Synoptical view

    Stock
    Abivax is listed on EURONEXT GROWTH PARIS since june 2015
    Truffle investment
    € 32M
abivax_xbx64.jpg

Management team

hartmut_ehrlich.jpg

Prof. Hartmut Ehrlich

CEO

didier_blondel.jpg

Didier Blondel

CFO

Board of Directors

joy_amundson.jpg

Joy Amundson

Partners

cnrs.png

In summary

Truffle Capital has created and invested in Abivax to develop two unique platforms that address huge medical needs and a multi-billion dollar market: viral diseases, particularly HIV/AIDS, inflammatory diseases, including digestive system diseases and liver cancer.

They talk about it

hartmut_ehrlich.jpg

We are now moving forward as quickly as possible with our phase 3 plan in ulcerative colitis as well as phase 2b/3 in Crohn’s disease to bring ABX464 to the many patients suffering from inflammatory bowel disease

Media

302.png

Next start-up

Acasi